CD19 and acute lymphoblastic leukemia: Four (29%) patients with LBCL and five (50%) patients with B-ALL exhibited low or negative CD19 expression at the time of progression after the treatment.148 A similar result was shown in 13 B-ALL patients, where 84.6% of patients achieved CR with dual CD19xCD22 CAR-T cell (SCRI-CAR19x22) therapy, and 95% were MRD-.